apoptosis XIAP FAF1 Fas/CD95 pathway NF-κB pathway A B S T R A C T Cell death depends on the balance between the activities of pro-and anti-apoptotic factors. X-linked inhibitor of apoptosis protein (XIAP) plays an important role in the cytoprotective process by inhibiting the caspase cascade and regulating pro-survival signaling pathways. While searching for novel interacting partners of XIAP, we identified Fas-associated factor 1 (FAF1). Contrary to XIAP, FAF1 is a pro-apoptotic factor that also regulates several signaling pathways in which XIAP is involved. However, the functional relationship between FAF1 and XIAP is unknown. Here, we describe a new interaction between XIAP and FAF1 and describe the functional implications of their opposing roles in cell death and NF-κB signaling. Our results clearly demonstrate the interaction of XIAP with FAF1 and define the specific region of the interaction. We observed that XIAP is able to block FAF1-mediated cell death by interfering with the caspase cascade and directly interferes in NF-κB pathway inhibition by FAF1. Furthermore, we show that XIAP promotes ubiquitination of FAF1. Conversely, FAF1 does not interfere with the anti-apoptotic activity of XIAP, despite binding to the BIR domains of XIAP; however, FAF1 does attenuate XIAP-mediated NF-κB activation. Altered expression of both factors has been implicated in degenerative and cancerous processes; therefore, studying the balance between XIAP and FAF1 in these pathologies will aid in the development of novel therapies.
Introduction
Apoptosis is a programmed cell death regulated by a large number of extracellular and intracellular signals that plays a key role in both embryonic development and adult homeostasis [1] . Molecular and biochemical data have shown that the inhibitor of apoptosis protein family (IAPs) regulates the apoptotic cell death program [2] . IAP family members are endogenous c-Asp protease (caspase) inhibitors that were first identified in baculoviruses for their ability to inhibit apoptosis in host cells [3] . Among the members of this family, the most thoroughly characterized is the X-linked inhibitor of apoptosis protein (XIAP), a potent inhibitor of apoptosis, whose deregulation has been correlated with various human pathologies. Indeed, XIAP is differentially overexpressed in many human cancers [4] and has been described as a chemoresistance factor in different tumors, thus becoming an important target in the development of efficient pharmacological therapies for cancer [5] . Mutations in the gene encoding XIAP result in a primary immunodeficiency [6] , and XIAP levels are reduced in Wilson's disease and other copper toxicosis disorders [7] .
XIAP is the only member of the family able to directly inhibit both initiation and execution of the caspase cascade [8] . XIAP contains three baculovirus IAP repeat (BIR) domains, which are followed by an ubiquitin-associated domain (UBA) and a RING-finger domain with E3 ubiquitin ligase activity [9] . The BIR 2 domain and N-terminal linker of XIAP bind and inhibit active caspase-3 and -7, whereas the BIR 3 domain binds and blocks caspase-9 [10, 11] . The RING domain of XIAP may act as an E3 ubiquitin ligase in the ubiquitination pathway to control the turnover of a number of cellular proteins as well as itself [12] . XIAP regulates intracellular signaling cascades, such as TGF-β, MAP kinase activation and the NF-κB pathway [13] [14] [15] [16] [17] . Overexpression of XIAP has been shown to enhance phosphorylation of AKT, and activate the JNK and NF-κB pathways [14, 18, 19] . Moreover, XIAP functions in an ubiquitin ligase-dependent manner to evoke a second wave of NF-κB activation, resulting in the modulation of NF-κB target gene expression [20] .
Several XIAP-interacting proteins have been described to bind to XIAP and negatively regulate its anti-apoptotic activity, thereby sensitizing cells to cell death. Some of these proteins, such as XAF1 [21] , Smac/Diablo [22, 23] and Omi/HtrA2 [24] , block XIAP inhibitory activity on caspases, while others, such as NRAGE [25] and SIVA [26] , interfere with the ability of XIAP to regulate other pro-survival pathways. To identify novel interacting proteins that modulate its cellular function, we used a truncated XIAP mutant as bait in a yeast two-hybrid screen. In this study, we identified and characterized the pro-apoptotic protein FAF1 as a new XIAP-interacting protein.
FAF1 is an evolutionarily conserved protein that was identified as a binding protein to the Fas/CD95 cytoplasmic domain using a yeast twohybrid screen in mice [27] . FAF1 is involved in diverse biological processes, such as the regulation of apoptotic cell death, the regulation of protein complex assembly, proteasomal ubiquitin-dependent protein catabolic process, inhibition of the chaperone heat shock proteins Hsc70 and Hsp70, and the regulation of axon targeting [27] [28] [29] [30] [31] . Among these biological activities, cell death plays a prominent role. FAF1 is involved in normal development and neuronal cell survival [32] , whereas deregulated expression of FAF1 may contribute to tumorigenesis [28] and to the pathogenesis of Parkinson disease [33] . FAF1 has been recently shown to have dual death-promoting mechanisms: a membrane receptor-dependent activation (FAS-DISC) and a receptor-independent Death Effector Filament (DEF)-formation [34, 35] . FAF1 is a 74-kDa protein, component of the death-inducing signalling complex (DISC) that directly interacts with distinct members of the Fas signalling pathway. The N-terminal domain (the Fasinteracting domain (FID)) mediates its binding with Fas/CD95 and the death effector domain interacting domain (DEDID) domain interacts caspase-8 and FADD. These interactions allow FAF1 to modulate the Fas-mediated apoptotic response [34] . FAF1 overexpression induces apoptosis in the absence of any extrinsic cell death signal [35] and is also involved in the regulation of NF-κB signalling. Thus, FAF1 suppresses NF-κB activation triggered by inflammatory mediators such as tumor necrosis factor (TNF-α), lipopolysaccharide (LPS) or interleukin-1β (IL1β) through either cytoplasmic sequestering of the NF-κB subunit p65/RelA [36] or the suppression of IKK Complex activation [37] .
We have analysed the functional role of their interaction since both XIAP and FAF1 play an opposite role in cell death and inversely regulate the NF-κB pathway. We aimed to confirm this interaction in eukaryotic cells, to establish the binding region of both proteins and to determine the intracellular distribution of both proteins in eukaryotic cells. Given that XIAP acts as an E3 ubiquitin ligase through its RING finger domain, we explored whether FAF1 is regulated by proteasomal degradation by XIAP. To gain further functional insight into their interaction, we tested whether XIAP is responsible for attenuating FAF1-induced apoptotic cell death or, by contrast, FAF1 acts by abrogating the cytoprotective activity of XIAP. Finally, we studied a possible antagonistic function of XIAP and FAF1 in regulating inflammation: FAF1 altering NF-κB stimulation induced by XIAP and/or XIAP affecting on FAF1-mediated NF-κB inhibition.
Material and Methods

Expression Constructs
Full-length human XIAP (1-497aa), XIAP-ΔRING (1-412aa), XIAP-Δ (BIR3-RING) (1-264aa), and XIAP-Δ(BIR1-BIR2) (265-497aa) were subcloned into the yeast GAL4 binding domain pGBKT7 vector (Clontech, USA) (XIAP-BD) and the eukaryotic expression pcDNA3 vector (ThermoFisher, USA) in frame with the c-myc-tag. The human full-length XIAP was subcloned into the prokaryotic expression vector pGEXT4 to obtain a Glutathione S-transferase fusion protein with XIAP (XIAP-GST). The human full-length FAF1 (1-650aa) was subcloned into the yeast GAL4 activation domain pGADT7 plasmid (Clontech, USA) (FAF1-AD) and the eukaryotic EGFPcI expression vector (EFGP-FAF1) (Clontech, USA). FAF1-FID (1-200aa), FAF-ΔCtDEDID (1-276aa) and FAF1-ΔNtDEDID (271-650aa) and FAF1 full-length were subcloned in the eukaryotic expression vector pcDNA3 in frame with the Hemagglutinin tag (HA).
Yeast two-hybrid screening
The Matchmaker Two-Hybrid System 3 (Clontech, Palo Alto, CA) was used to screen a human fetal brain cDNA library (Clontech, USA) with the truncated mutant of XIAP (XIAP-ΔRING) as bait, following the manufacturer's instructions. Co-transformation of the bait and the prey human fetal brain library was performed according to the lithium acetate transformation protocol using yeast strain AH109 under highly stringent conditions with medium lacking Adenine (− A), Histidine (− H), Leucine (− L), and Tryptophan (−W), supplemented with 35 mM 3-amino-1,2,4-triazole, (3-AT) (Sigma, UK) and a total of 1 × 10 8 transformants was screened. Yeast colonies were assayed for β-galactosidase activity using a filter lift assay. Yeast back assays were performed with co-transformation of the following constructs: FAF1-AD, XIAP-BD, binding domain GAL4 (BD), activation domain GAL4 (AD) and fusion GAL4 control (Lamin-BD). Survival of the co-transformed yeast cultures was analysed in nutritional selection plates and the activity of the MEL-1 reporter gene by using X-α-Gal (Sigma, UK) as substrate. Co-transformed yeast cultures of FAF1 and different XIAP construct were analysed by using liquid β-galactosidase assay. The βgalactosidase liquid assay was performed with colonies co-expressing full-length or deletion constructs of XIAP in pGBKT7 vector and the FAF1 in pGADT7 vector. Reactions were carried out at 30°C of in the presence of 4 μg/ml o-nitrophenyl β-D-galactopyranoside (ONPG). Absorbance at 420 nm was determined and calculated as unit activity/min.
Cell Culture and cell transfection
Human Embrionic Kidney (HEK293T) cells were grown in Dulbecco's Modified Eagle's Medium (Lonza, Switzerland) enriched with 10% fetal bovine serum and 1% L-Glutamine (Lonza, Switzerland). Human cervical cancer cell line (HeLa) was grown in Eagle's Minimal Essential Medium (Lonza, Switzerland) enriched with 10% fetal bovine serum, 1% Pyruvate (Lonza, Switzerland), 1% Non-Essential-Amino-Acids (Lonza, Switzerland) and 1% L-Glutamine (Lonza, Switzerland). Human neuroblastoma (SH-5YSY) was grown in a 1:1 mixture of Eagle's Minimal Essential Medium (Lonza, Switzerland) and Ham's F12 medium supplemented with 10% fetal bovine serum, 1% Pyruvate (Lonza, Switzerland) and 1% Non-Essential-Amino-Acids (Lonza, Switzerland). Transient transfections were performed during 24-48 h by using Transfectin® (Bio-Rad, USA). To study the endogenous expression level of FAF1 in the presence of increasing XIAP levels, HEK293T cell cultures were transfected for 36 h with a total of 10 μg/ ml of plasmid DNA (increasing concentrations of XIAP (0, 1, 2, 4, 6 and 8 μg/ml) adjusted with pcDNA3 vector DNA).
GST Pull-down Assay
After 48 h of transfection with EGFP-FAF1 construct HeLa cells were harvested in lysis buffer (1 mM HEPES, 2.5 mM NaCl and 0.5% Nonidet-P40 (IGEPAL CA-630, Sigma)). GST and GST-XIAP proteins were expressed in E. coli BL21(DE3) cells, lysated and purified with glutathione-Sepharose 4B beads (GE Healthcare, USA) as specified by the manufacturer (detected by Western blotting with goat anti-GST (AB_771429, GE-healthcare, UK). For binding assay, 100 μg of HeLa cell lysate were incubated with 1 μg of either GST or GST-XIAP proteins for 4 h at 4°C in lysis buffer. Samples were washed four times with lysis buffer, and the bound proteins were separated by SDS-PAGE and detected by Western blotting with mouse anti-GFP (AB_390913, Roche, Switzerland).
Immunoprecipitation assays
After 36 h of transfection with EGFP-FAF1 construct, HeLa cell culture was harvested and lysated with buffer lysis (1 mM HEPES, 2.5 mM NaCl and 0.5% Nonidet-P40). Cell extract was used for immunoprecipitation with 30 μl of protein A/G Plus-sepharose (Novagen, Germany) and 0.5 μg/ml of rabbit anti-XIAP (AB_2214870, CST, USA). Immunoprecipitation was performed overnight at 4°C, washed five times with lysis buffer and resolved by SDS-PAGE. Immunocomplexes were transferred to 0.45 μm PVDF membrane (Millipore, USA) and analysed by Western blot using mouse anti-GFP (AB_390913) and anti-mouse secondary antibodies coupled to Horseradish Peroxidase (HRP) (AB_228341)(1:10,000, Thermo Fisher Scientific). To check the successful pull-down of XIAP, the immunocomplexes were immunoblotted with mouse anti-XIAP (AB_1572759). XIAP/FAF1 endogenous immunoprecipitation studies were carried out similarly. After 24 h of seeding, HeLa or SH-5YSY cells were harvested and lysated with buffer lysis (1 mM HEPES, 2.5 mM NaCl and 0.5% Nonidet-P40). Cell extract was immunoprecipitated overnight at 4°C with 30 μl of protein A/G Plus-sepharose (Novagen, Germany) and 0.5 μg/ml of mouse anti-XIAP (AB_1572759) or IgG isotype antibodies (IP control) (AB_10829607, Cell signaling, USA). The extracts were washed five times with lysis buffer and resolved by SDS-PAGE. Immunocomplexes were transferred to 0.45 μm PVDF membrane and analysed by Western blot using anti-FAF1 (AB_183045, Abcam, UK) and secondary antibodies coupled to HRP. Successful pull-down of XIAP was checked with rabbit anti-XIAP (AB_2214870). To study XIAP-TAB1 interaction, HEK293T cells were transfected during 36 h with a total of 10 μg/ml of plasmid DNA: c-myc-XIAP construct (1 μg/ml) and increasing amounts of FAF1 plasmid (0, 1, 2, 4, and 8 μg/ml) adjusted with pcDNA3 vector DNA. Cells were treated with TNF-α (20 ng/ml) for 30 min and lysated. Cell lysates were immunoprecipitated against cmyc antibodies (AB_390912, Roche, Switzerland) and then immunoblotted with anti-TAB1 (AB_2140247, CST, USA) and secondary antibodies coupled to HRP. To check the successful pull-down of XIAP, the immunocomplexes were also immunoblotted with rabbit anti-XIAP (AB_2214870). To study FAF1-p65/RelA interaction, HEK293T cells were co-transfected with HA-FAF1 and increasing amounts of XIAP plasmid or its deletion mutant (XIAP-ΔRING). After 36 h, the cells were treated with TNF-α (20 ng/ml) for 30 min. The cell lysates were immunoprecipitated with HA antibodies (AB_514505, Roche, Switzerland) and then immunoblotted with anti-p65/RelA (AB_1078218, CST, USA). To check the successful pull-down of FAF1, the immunocomplexes were immunoblotted with rabbit anti-FAF1 (AB_183045).
Viability assay
24 h after transfection, HeLa cells were treated with 50 ng/ml anti-Fas (AB_309653, Millipore, USA) and Cycloheximide (CHX) (2.5 μM) (Sigma, UK) for 16 h, then fixed in 4% Paraformaldehide during 20 min, permeabilized with 100 μM Digitonin, washed with PBS and blocked with 1% horse serum (HS) in PBS. Cells were incubated with primary antibodies: rabbit anti-XIAP (1:500) (AB_2214868, CST, USA) and/or mouse anti-GFP (1:1000) (AB_390913) in 0.1% HS-PBS + 100 μM Digitonin during 2 h at room temperature (RT). Cells were washed three times with PBS and incubated for 1 h at RT with the secondary antibodies Alexa 594 anti-rabbit (AB_2534079) and Alexa 488 anti-mouse (AB_2534088) (Thermo Fisher Scientific, USA) (1: 1000) in 0.1% HS-PBS, during. After three washes of 5 min in PBS cells were stained with 4′,6-diamidino-2-phenylindole (DAPI) (1:1000) (Sigma, UK). The condensation of the nucleus was assessed as a morphological marker of apoptosis.
Caspase activation assay
Hela cells were transiently cotransfected for 36 h with pcDNA3-cmyc-XIAP, pcDNA3-HA-FAF1 and pcDNA3. Cells were treated with anti-FAS (100 ng/ml) and CHX (2.5 μM) for 16 h. Cell lysates were obtained with the lysis buffer (25 mM HEPES, 150 mM NaCl, 1% Nonidet-P40, 1% DOC, 10% Glycerol, 10 mM MgCl 2 , 2 mM CHAPS, 0.1% SDS, 2 mM EDTA, 1 mM orthovanadate, 25 mM NaF and protease inhibitor cocktail (Roche, Switzerland)). Proteins were resolved in SDS-PAGE gel and transferred to nitrocellulose membranes (Millipore, USA) in presence of Methanol 20%. Membranes were blotted with rabbit primary antibodies (1:1000), anti-caspase-3 (AB_10694681, CST, USA), anti-cleaved caspase-3 (AB_2341188, CST, USA), anti-caspase 7 (AB_2228313, CST, USA), anti-PARP (AB_10694650, CST, USA), or the mouse primary antibodies (1:1000) anti-caspase 8 (AB_10694352, CST, USA), anti-caspase 9 (AB_2068620, CST, USA), anti-c-myc (AB_390912) and anti-HA (AB_514505) followed by mouse (AB_228341) or rabbit (AB_228307) HRP-conjugated secondary (1:10,000, Thermo Fisher Scientific).
Caspase biochemical assay
The Caspase-Glo 3/7 and Caspase-Glo 8 (Promega, USA) kits were employed to assay the caspase activity. HeLa cell cultures were transiently transfected with XIAP, FAF1 or both at different molar ratio and treated with anti-FAS 100 ng/ml (AB_309653) and CHX (2.5 μM) overnight. Lysates were obtained following provider instructions and luminiscense was measured in a microplate-reader (TECAN, Switzerland).
Endogenous protein immunocytochemistry
HeLa cell cultures were plated in an eight well slide for 48 h. Afterwards, cells were washed with PBS, fixed in 4% Paraformaldehide during 20 min, permeabilized with 100 μM Digitonin, washed with PBS and blocked with 1% HS in PBS. Cells were incubated for 2 h at RT in 0.1% HS-PBS + 100 μM Digitonin with primary antibodies: (1:500) rabbit anti-FAF1 (AB183045) and (1:500) mouse β-tubulin (AB_477580, Sigma, UK) or (1:500) mouse anti-XIAP (AB_1572759). Next, cells were washed three times for 5 min with PBS and incubated for 1 h at RT in 0.1% HS-PBS with the secondary antibodies (1:1000) Alexa 594 anti-rabbit (AB_2534079) and (1:1000) Alexa 488 antimouse (AB_2534088). After three washes of 5 min in PBS, cells were incubated for 5 min with DAPI (1:1000)(Sigma, UK) + PBS and washed three times with PBS. Finally, cells were examined by confocal microscopy (SP5 Leica, Germany) and the images were analysed by ImageJ software (NIH, USA) and JACOP plugIn [38] .
Luciferase Reporter Gene Assays
HEK 293 T cells were transiently transfected with pcDNA3-NF-κB promoter-luc (plasmid encoding κB luciferase reporter construct) and PcDNA3-Renilla (encoding Renilla luciferase) together with pcDNA3 (Control), pcDNA3-c-myc-XIAP, pcDNA3-HA-FAF1, pcDNA3-c-myc-ΔRING, and pcDNA3-HA-FAF1-ΔCtDEDID. We employed control plasmid pcDNA3 to adjust the total amount of transfected DNA. Cells were left untreated or were stimulated at 36 h post-transfection with 20 ng/ ml TNF-α (Peprotech, USA) for 30 min. Cell lysates were assayed for luciferase activity using the Dual-Glo Luciferase kit following the manufacturer's protocol (Promega, USA).
Ubiquitination assay
HEK 293 T cell cultures were transiently cotransfected for 36 h with Ubiquitin-His construct (pMT107, kindly provided by Dirk Bohmann), pcDNA3-c-myc-XIAP, pcDNA3-c-myc-XIAP-ΔRING, control pcDNA3 and pEGFP-FAF1 or pcDNA3-HA-FAF1. Cell cultures were treated for 4 h with 40 μM of the MG132 (Sigma, UK) as a proteosome inhibitor. Cell extracts were obtained with buffer lysis (1 mM HEPES, 2.5 mM NaCl and 0.5% Nonidet-P40), purified with His-Spin Protein miniprep (Zymo research, USA) and immunoblotted with antibodies against GFP (AB_390913) or HA (AB_514505).
Cellular fractionation
HEK 293 T cell cultures were transiently cotransfected with pcDNA3-c-myc-XIAP, pcDNA3-HA-FAF1 or pcDNA3-HA-FAF1 + pcDNA3-c-myc-XIAP constructs for 36 h and treated with 20 ng/ml TNF-α (Peprotech, USA) for 30 min. Afterwards, cells were washed with ice-cold PBS + 1 mM EDTA, scraped and centrifuged at 3400 × g, 5 min at 4°C. Cell pellet was resuspended in 4°C buffer A (10 mM HEPES, 50 mM NaCl, 0.1 mM EDTA, 0.5 mM Sacarose, 0.5% Triton-× 100, 1 mM dithiothreitol (DTT), 100 mM NaF and protease inhibitor cocktail) and centrifuged 200 × g for 10 min 4°C. Supernatant was centrifuged at 18000 × g for 15 min (4°C) to obtain the cytosolic extract. The pellet was resuspended in an ice-cold buffer B (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT and protease inhibitor cocktail) and centrifuged at 250 g for 5 min. This pellet was lysed with buffer C (10 mM HEPES, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.1% Nonidet-P40 and protease inhibitor cocktail) and centrifuged at 18000 g for 15 min to obtain the nuclear fraction. Cytosolic and nuclear lysates were resolved in SDS-PAGE gel and transferred to PDVF membranes (Millipore, USA), which were blotted with antibodies against p65/RelA (AB_1078218), PARP (AB_10694650), β-tubulin (AB_477580), HA-FAF1 (AB_514505) or cmyc-XIAP (AB_390912).
Data analysis
All data are expressed as mean ± standard deviation (SD) or mean ± standard error of the mean (SEM). Statistical significance of the distinct assays was determined by the parametric paired Student's ttest. All analyses were performed using Prism Software 5 (GraphPad Software Inc.). Differences with P < 0.05 were considered statistically significant.
Results
Identification of FAF1 as a XIAP-interacting protein
We performed a yeast two-hybrid screen to find new regulators of XIAP activity. Hence, we identified FAF1 as an interacting protein after screening a fetal human brain library using a XIAP deletion mutant (UBA and RING domains deletion) as bait. A total of 55 positives clones were obtained from~108 transformants including two clones carrying the entire coding sequence of FAF1. Back transformation of yeast with human FAF1 and distinct prey constructs, including wild-type human XIAP, confirmed the interaction (Fig. 1A) .
To further verify the XIAP and FAF1 interaction observed in yeast, we next performed GST pull-down experiments with XIAP-GST or GST overexpressed in E. coli (Fig. 1B) . The full coding sequence of human FAF1 was subcloned into the mammalian expression vector EGFPcI to overexpress the fusion protein EGFP-FAF1 in the human HeLa cell line. These cell cultures were lysed to obtain total protein extracts, which were probed for interaction with either XIAP-GST fusion protein or GST protein (control). As observed in yeast, a clear pull-down was observed only when XIAP and FAF1 were present. No interactions were observed between FAF1 and control GST or between XIAP and control EGFP. To independently confirm the interaction of FAF1 with XIAP observed in the yeast two-hybrid system and the GST pull-down assays, we performed coimmunoprecipitation assays of endogenous proteins ( Fig. 1D and E) . We evaluated the endogenous levels of both proteins in the human cell lines HeLa, HEK293T and SH-SY5Y ( Fig. 1C ) and observed a higher expression of both proteins in HeLa and SH-SY5Y cells, which were employed for further immunoprecipitation analysis. We first transiently transfected HeLa cells with EGFP-tagged FAF1 or EGFP and the lysate was immunoprecipitated against endogenous XIAP protein to subsequently immunoblot using GFP antibody. As shown in Fig. 1D , FAF1 was detectable after immunoprecipitation with XIAP antibodies in EGFP-FAF1-expressing cells lysates but was not present in EGFP control lysates.
Similarly, we performed coimmunoprecipitation assays of endogenous XIAP and FAF1 proteins in HeLa and SH-SY5Y cells (Fig. 1E ). Cell extracts were immunoprecipitated against endogenous XIAP and the immunoblot using FAF1 antibody revealed a clear signal of the endogenous co-immunoprecipitation of XIAP and FAF1 but not using control antibody (isotype IgG). The above studies demonstrated the endogenous interaction of FAF1 and XIAP in eukaryotic cells.
The DEDID domain of FAF1 specifically interacts with XIAP
To define the interacting region between human XIAP and human FAF1, we first transformed yeast with the FAF1 expression plasmid and either the wild type XIAP plasmid or distinct truncated XIAP mutant expression plasmids and quantified the β-galactosidase activity (Fig. 2B ). The results confirmed the direct interaction between fulllength FAF1 and the native XIAP (P < 0.05, n = 3, T 2 = 8.414) and revealed the specific interaction of FAF1 and the XIAP deletion mutants, XIAP-ΔRING (P < 0.05, n = 3, T 2 = 6.414) and XIAP (ΔBIR3-RING) (P < 0.05, n = 3, T 2 = 4.428), but not with XIAP (ΔBIR1-2) (n = 3, T 2 = 0.1720).
In parallel, we employed co-immunoprecipitation studies to establish the domains involved in the interaction between XIAP and FAF1. Three distinct deletion mutants of c-myc-tagged XIAP (Fig. 2C ) were coexpressed with HA-tagged FAF1 in HEK-293 T cells. As shown in Fig. 2C , wild-type XIAP and the XIAP-ΔRING truncated mutant, but not the XIAP (ΔBIR1-2) or XIAP (ΔBIR3-RING) mutants, co-immunoprecipitated with FAF1. Therefore, a minimal specific interaction region is defined by FAF1 association with the N-terminal deletion mutant of XIAP spanning the BIR domains region and its failure to associate with the C-terminal deletion mutant of XIAP expressing the UBA and RING finger domains. Similarly, we prepared several deletion mutants of HAtagged FAF1 (Fig. 2D ), which were co-expressed with c-myc-tagged XIAP into HEK293T. Only FAF1 and the FAF1 mutant protein containing the FID domain and N-terminal DEDID domain co-immunoprecipitated with XIAP ( Fig. 2D ).
Taken together, these results confirmed the interaction between FAF1 and XIAP, initially observed in yeast, in different eukaryotic cell lines namely HeLa, SH-5YSY. This interaction occurs between the Nterminal region of XIAP, which spans between BIR1 and BIR3 and the DEDID domain of FAF1.
Colocalization studies
Double immunohistochemical labelling and confocal microscopy was performed to further explore whether XIAP and FAF1 colocalize within the cell. FAF1 has been shown to localize to the cytoplasm of NIH3T3 cells, BOSC23 cells and the cytosol and cytoplasmic membrane in Jurkat cells [39] . Similarly, FAF1 colocalizes with Fas-DISC in the plasma membrane of Jurkat cells before and after Fas stimulation [34] . Image analysis revealed that both proteins were distributed throughout the cytosol and plasma membrane, while scarce labelling was observed in the nucleus of HeLa cells (Fig. 3A) .
Quantification of FAF1 and XIAP label colocalization from the confocal images was performed using distinct number of specialized coefficients (Fig. 3B) . The analysis showed a high level of overlapping for both proteins compared to unspecific FAF1 and β-tubulin overlapping ( Fig. 3B) . Similar results were observed in the cellular distribution of FAF1 and XIAP overexpressed into HeLa cells (Suppl. Fig. A) . These observations reveal a distribution of FAF1 and XIAP in which regulatory interaction could potentially occur.
FAF1 degradation is regulated by XIAP
Previous studies have shown that XIAP acts as an E3 ubiquitin ligase through its RING finger domain [40] , which enhances its anti-apoptotic effect by promoting the proteasomal degradation of several proapoptotic factors, including caspases, Omi/HtrA2 and SIVA [26, [41] [42] [43] . To determine whether XIAP could regulate the expression of FAF1 by proteasomal degradation, we first examined the endogenous expression level of FAF1 in the presence of increasing amounts of XIAP. HEK293T cell cultures were transfected with different concentrations of XIAP, and the cell extracts were immunoblotted against FAF1. We observed a reduction of endogenous FAF1 levels when the XIAP concentration was increased ( Fig. 4A) . Conversely, we observed a moderate increment of endogenous FAF1 using silencing RNA to downregulate XIAP. HEK293T cells were transfected with scramble and XIAP Silencer pre-designed siRNAs for 36 h and immunoblotted with anti-bodies against endogenous XIAP and FAF1 (Fig. 4D ). This experiment showed that reduced XIAP levels results in higher levels of FAF1. However, no reduction of endogenous FAF1 is observed in presence of increasing concentrations of the XIAP mutant XIAPΔRING ( Fig. 4B ).
Considering these results, we next examined whether FAF1 is a substrate of the ubiquitin-protein ligase of XIAP. HEK293T cells were co-transfected with plasmids encoding Histidine-tagged ubiquitin, wild type or mutant c-myc-XIAP together with EGFP-FAF1 ( Fig. 4C , left panels). The same experiment was performed HA-FAF1 ( Fig. 4C , right panels). Lysates were prepared, and exogenous ubiquitin was precipitated in Nickel columns. FAF1 protein attached to ubiquitin was immunoblotted with anti-EGFP or anti-HA antibodies. Lanes with either the control or XIAP (XIAP-ΔRING) deletion mutant exhibited reduced amounts of ubiquitinated proteins after immunoprecipitation compared with that of the wild type XIAP. Ubiquitinated EGFP-FAF1 appeared at and above 112 kDa and ubiquitinated HA-FAF1 appeared at and above 85 kDa ( Fig. 4C ). Therefore, polyubiquitinated FAF1 was detected only in the presence of XIAP protein with functional E3-ligase activity, suggesting that the intracellular presence of FAF1 is regulated by proteasomal degradation after ubiquitination by XIAP.
XIAP blocks FAF1-mediated cell death
FAF1 is involved in the regulation of apoptotic cell death and participates in regulating neurodevelopment as a pro-apoptotic factor. Moreover, FAF1 overexpression in Jurkat cells causes significant apoptotic death [34] . To determine whether XIAP alters FAF1-induced These results showed that the pro-apoptotic action of FAF1 or activation of the Fas pathway in the HeLa cell line may be counterbalanced by the over-expression of XIAP. Similar results were obtained using the HEK293T cell line and staurosporine as the apoptotic inducer (Supp. Fig. C) .
We next analysed the caspase cascade activation, to determine at which level XIAP interferes in FAF1-mediated apoptosis (Fig. 6 ). First, we studied whether XIAP interferes with the direct interaction between FAF1 and caspase-8. Lysates obtained from HeLa cell cultures which overexpressed HA-tagged FAF1 and different amounts of XIAP were immunoprecipitated with HA antibodies and immunoblotted against caspase-8. We did not observe a change in the immunoprecipitated caspase-8 levels despite of increasing amounts of XIAP, which would not suggest a direct interference of XIAP between FAF1 and caspase-8 (Supp . Fig. B) .
To analyse the apoptotic cascade, HeLa cell cultures overexpressing XIAP, FAF1 or XIAP/FAF1 were lysed and immunoblotted with anticaspase-8, anti-caspase-9, anti-caspase-3, anti-caspase-7 and anti-PARP. Transiently transfected HeLa cells showed no clear activation of caspase-9 ( Fig. 6A ) but a reduction in the procaspase-8 levels as well as in the levels of the effectors procaspase-3 (32 kDa) and procaspase-7 was observed in FAF1 overexpressing cells. Similarly, we detected the cleaved intermediate p43/p41, the active fragment p18 of caspase-8 and the endogenous large fragment (17/19 kDa) of activated caspase-3 in the lysates of FAF1 overexpressing cells. Interestingly, these fragments of activated caspase-8 and caspase-3 are not present in XIAP + FAF1 overexpressed cells.
To further confirm this caspase cascade activation, we analysed the degradation of poly (ADP-ribose) polymerase (PARP), a caspase-3 and -7 substrate. We observed an increase in PARP degradation due to caspase cleavage only in the FAF1 cell lysates. HeLa cells stimulated with the agonistic human antibody against Fas exhibited increased caspase activation. As shown in Fig. 6A , the cleaved intermediate of caspase-8 (p43/p41) was present in all cases, but differences in activation levels were observed depending on which protein(s) was overexpressed and the conditions employed to treat the cells. Thus, in resting condition, cells that overexpressed FAF1 showed an increased level of processed caspase-8 proform compared with the control, XIAP or cotransfected FAF1/XIAP cells. Upon Fas stimulation it was not possible to observe these differences. Similarly, detection of caspase-8 activity using a luminescent assay demonstrated no significant differences between non-stimulated HeLa cell cultures, but higher caspase-8
XIAP-Δ(BIR3-RING)
(264aa) Nt Ct activity was observed when FAF1 was overexpressed after apoptotic stimulation (anti-Fas) ( Fig. 6C ).
XIAP-ΔRING
We observed, in stimulated condition, incremental processing of endogenous caspase-9, caspase-3 and caspase-7 proform in FAF1 overexpressed cells as well as a reduction of the full-length form and incremental processing of PARP. Interestingly, cell cultures that coexpressed XIAP and FAF1 exhibited attenuated PARP degradation and caspase cascade activation (caspase-3, −7 and − 9). This caspase-3 and -7 activation was further confirmed by in vitro luminescent assays in transiently transfected HeLa cells with XIAP, FAF1 and XIAP with equal or different FAF1 molar ratios in both the absence and presence of Fas stimulation ( Fig. 6B and C) . In absence of Fas stimulation, increased caspase-3/7 enzyme activity was observed in FAF1 cell lysates compared to control (P < 0.01, n = 3, T 2 = 9.152) ( Fig. 6B ), but a clear reduction of caspase-3/7 activity was observed in both XIAP and cotransfected FAF1/XIAP cell lysates. A higher caspase-3/7 enzyme activity was detected upon Fas stimulation in FAF1 cell lysates (compared to control: P < 0.05, n = 5, T 4 = 2.9355) and XIAP cell lysates significantly reduced caspase-3/7 activity (compared to control: P < 0.05, n = 5, T 4 = 4.223) even in presence of FAF1 (FAF1/XIAP (1:1) compared to FAF1: P < 0.01, n = 5, T 4 = 6.9327) or FAF1/XIAP (2:1) compared to FAF1: P < 0.05, n = 5, T 4 = 3.0323. Similar results were obtained for effector caspases activity employing the XIAP deletion mutant (Fig. 6D ) in Fas-unstimulated HeLa cell cultures. Together, these results confirmed the attenuation of cell death by XIAP after overexpression during FAF1-mediated apoptosis.
NF-κB pathway inhibition by FAF1 is attenuated by XIAP
NF-κB signaling is regulated by XIAP and FAF1. Although best known for its ability to inhibit caspases, XIAP is also able to mediate the MAP kinase and NF-κB pathways [13, 14, 17, 44] . XIAP has been shown to enhance the NF-κB pathway, which relies on its ubiquitin-binding ability, E3 ligase activity and interaction with the TAK1 binding protein (TAB1) through its BIR1 domain [9, 17] . Conversely, FAF1 acts as a negative regulator of the NF-κB pathway through the specific binding and cytoplasmic retention of NF-κB p65 as well as the inhibition of IKK activation [36, 37] .
We performed reporter gene assays to investigate whether FAF1 interferes with XIAP-mediated NF-κB stimulation. As shown in Fig. 7A , an activation of NF-κB signaling occured when XIAP was overexpressed but it was reverted by FAF1 overexpression in a dose dependent manner. This effect was observed in both the absence and presence of TNF-α stimulation. Because we defined the binding region of FAF1 using specific deletion mutants, we investigated the effect of the deletion mutant of FAF1(FAF1-ΔCtDEDID) in XIAP-induced NF-κB Similarly to wild-type FAF1, we observed that FAF1-ΔCtDEDID repressed NF-κB activity in non-stimulated and TNF-α-stimulated HEK293T cell cultures (Fig. 7B ). XIAP and FAF1-ΔCtDEDID co-expressed cell cultures showed no changes in nonstimulated conditions (Supp. Fig. G) , but a significant reduction of NF-κB XIAP-induced stimulation was observed in the presence of TNF-α (Fig. 7B) . The NF-κB stimulation produced by XIAP-TAK1 depends on the RING domain and the interaction between TAB1 with the BIR1 domain of XIAP [17] . Based on the above XIAP/FAF1 inmunoprecipitation results, we examined whether FAF1 interferes with XIAP-mediated NF-κB activation through direct binding of XIAP. Thus, we examined whether FAF1 disrupts the XIAP-TAB1 interaction in the presence of increasing expression of FAF1. Cell lysates from transiently co-transfected FAF1 and XIAP cell cultures (increasing amounts of FAF1 DNA) were immunoprecipitated with antibodies against XIAP and subsequently immunoblotted against TAB1. As shown in Fig. 7C , no changes were observed in immunoprecipitated endogenous TAB1. Therefore, FAF1 may alter XIAP-mediated NF-κB stimulation through direct inhibition of the NF-κB cascade but not through direct interference between XIAP-TAB1.
We next examined the effect of XIAP overexpression on FAF1mediated NF-κB inhibition. Thus, we similarly performed gene luciferase assays with a XIAP deletion mutant, XIAP-ΔRING, which also interacts with wild type FAF1 (Fig. 8A) . This mutant lacks the UBA and RING domains, which are essential for NF-κB induction. As shown in Fig. 8A , we observed that the XIAP mutant in HEK293T cells is unable to induce NF-κB activation, and co-expression of XIAP-ΔRING and FAF1 resulted in an inhibited NF-κB response. Despite the binding between the XIAP mutant and FAF1, this interaction does not alter FAF1-induced inhibition. Because the binding region between FAF1 and XIAP was defined by immunoprecipitation studies on the aminoterminal DEDID region, we therefore investigated whether XIAP interferes with the FAF1 p65 binding site.
We prepared cell extracts from HEK293T cells transiently transfected with FAF1 and increasing amounts of XIAP and stimulated with TNF-α ( Fig. 8B left panel) . After immunoprecipitation with the HAantibody (HA-tagged FAF1) and immunoblot analysis (anti-NF-κB p65), we observed a dose-dependent reduction of the endogenous NF-κB p65 subunit. This reduction in the immunoprecitpitated NF-κB p65 subunit may be due either to direct interference of XIAP or the FAF1 degradation by XIAP (Fig. 5) . In order to clarify the contribution of XIAP in the NF-κB p65-FAF1 interaction, we prepared cell extracts from HEK293T cells transiently transfected with FAF1 and XIAP or XIAP-ΔRING and stimulated with TNF-α. Lysates were immunoprecipitated against HA-FAF1 and performed an immunoblot of NF-κB p65 subunit. The Fig. 8B (right panels) shows no signal of FAF1-p65 in presence of XIAP or XIAP-ΔRING, suggesting that the interaction between XIAP and FAF1 is sufficient to interfere in FAF1-p65 interaction.
We further confirmed this interference of XIAP by investigating the translocation of p65/RelA from the cytosol to the nucleus. HEK293T cells were transfected with XIAP, FAF1 and XIAP + FAF1, stimulated with TNF-α, and nuclear or cytosolic fractions were extracted (Fig. 8C ). We observed that the endogenous NF-κB p65 subunit accumulates in the nucleus in both control and XIAP-overexpressing cells and is reduced in FAF1-overexpressing cells. Interestingly, the translocation of p65/RelA into the nucleus of FAF1-XIAP-overexpressing cells was increased compared with the extract from FAF1 cells. These results suggest that XIAP alters FAF1 inhibition of the NF-κB cascade through the interference of FAF1 cytosolic p65 sequestration. 
Discussion
In this study, we characterized the interaction between the proapoptotic protein FAF1 and anti-apoptotic protein XIAP. We first observed the XIAP-FAF1 interaction in a yeast two-hybrid assay and confirmed it using yeast, GST pull-down and co-immunoprecipitation assays. This is the first time that an interaction between XIAP and FAF1 has been demonstrated, even though Kinoshita et al. [45] were unsuccessful in demonstrating the interaction of these two proteins using immunoprecipitation assays. The interaction occurs between the DEDID domain of FAF1 and the region spanning the BIR domains of XIAP. According to yeast ONPG assays, FAF1 binds specifically to the BIR1-BIR2 domains of XIAP. However, co-immunoprecipitation assays in human cells only confirmed the interaction of FAF1 with the entire BIR domain region of XIAP. This discrepancy may be due to the distinct specificity and sensitivity of both assays. More sensitive colorimetric yeast assays depend on transcriptional activation resulting from the interaction between fusion proteins of XIAP or FAF1 with the GAL4 domains (binding and activation domains respectively) inside the nucleus, whereas more specific immunoprecipitation relies on the direct interaction of wild type human proteins with small tag (c-myc and HA). Both assays are consistent to support an interaction of FAF1 with the region than spans three BIRs domains of XIAP but a crystallographic study is needed to define the precise binding region between XIAP and FAF1.
Although we firmly established the FAF1-XIAP interaction at a molecular level, the seclusion of both proteins in distinct cellular organelles may prevent their actual interaction. This possibility is exemplified by the pro-apoptotic factors Omi/HtrA2 and Smac/ DIABLO, which are located in the mitochondrial periplasmic space and only interact with cytoplasmic XIAP when released into the cytosol following mitochondrial membrane permeabilization [23, 24] . However, present and previous studies indicate that both FAF1 and XIAP reside in the cytoplasm and nucleus of different cell types [34, 46, 47] . Moreover, our confocal analyses specifically demonstrated that the labelling of both proteins overlaps in the cytoplasm without any barrier preventing interaction in HeLa cells.
Different pro-apoptotic factors, such as Smac/Diablo, Omi/HtrA2 or XAF1, inhibit XIAP function through interaction with BIR domains [21, 23, 24] , which raises the possibility that FAF1-XIAP interaction would modulate XIAP. Interaction with FAF1 may directly block XIAP activity on effector caspases. However, our co-expression experiments in HeLa cells under apoptotic stimulation demonstrated that FAF1 is not able to abrogate the cytoprotective activity of XIAP. In this respect, FAF1 resembles the AIF protein, an interacting partner of the BIR2 domain of XIAP that does not prevent XIAP-mediated caspase inhibition [48] .
In contrast, the present analyses suggest that XIAP inhibits FAF1induced cell death. Overexpression of FAF1 sensitizes HeLa and other cell lines to cell death (present results and [32, 33, 35, 49, 50] ) through the activation of caspase-8 and the subsequent activation of effector caspases. Our experiments with HeLa cells showed that when coexpressed with XIAP, FAF1 is no longer able to induce cell death, even under Fas/CD95 stimulation. XIAP blocks the pro-apoptotic activity of FAF1 by inhibiting the activity of effector caspases, which agrees with previous studies in hepatocytes under CD95L/FASL stimulation [51] . XIAP also causes reduced proteolytic processing of caspase-8 and, subsequently, effector caspase-3 and -7 induced by FAF1. Because XIAP specifically interacts with the N-terminal region of the DEDID domain of FAF1, which is the domain that interacts with the DED domain of caspase-8 and FADD to form the DISC complex [34] , XIAP may attenuate FAF1-induced activation of caspase-8 by direct interference through the DEDID domain. However, our results show that XIAP does not interfere with the interaction of FAF1 and caspase-8 (Supp . Fig. B ). Further analyses are necessary to determine whether XIAP alters direct FADD-FAF1 binding. Alternatively, XIAP may attenuate caspase-8 activation by regulating FAF1 abundance through ubiquitination. XIAP contains a RING domain with E3 ubiquitin ligase activity, which catalyzes the ubiquitination of several pro-apoptotic interacting proteins to induce proteasomal degradation [40, 43, 52] . Although we did not observe a decrease in the expression of FAF1 when XIAP, which were performed using XIAP and FAF1 overexpressed cell cultures, our studies indicate that XIAP promotes the ubiquitination of FAF1 and may thus reduce the FAF1 concentration and caspase-8 activation. In summary, XIAP indirectly blocks FAF1-induced apoptotic cell death by inhibiting effector caspases and may directly regulate FAF1 levels through ubiquitination. XIAP may also interfere with FAF1 and DISC components in caspase-8 activation.
In addition to their role in apoptosis, XIAP and FAF1 also regulate cell survival through opposing effects on the NF-κB signaling pathway ( Figs. 7 and 8) . FAF1 inhibits the NF-κB pathway after stimulation with inflammatory factors (TNF-α, IL1β, LPS) by two alternate mechanisms: 1) binding the DEDID domain to the p65/RelA subunit of NF-κB to sequester it and prevent NF-κB translocation into the nucleus and 2) FID domain interaction with IKKβ to disrupt the formation of the IKK complex [36, 37] . In contrast, XIAP bridges TGF-β and BMP type I receptors to TAK1 to activate the NF-κB pathway [13, 16, 17] . XIAP activates TAK1 via the interaction of its BIR1 domain with TAB1 protein, while the RING domain of XIAP interacts with TGF-β and BMP type I membrane receptors [17] . In addition, XIAP can interact with and ubiquitinates MEKK2 to induce a second wave of NF-κB nuclear translocation, which leads to prolonged activation of this pathway [20] .
In agreement with previous studies [19, 36] , we confirmed that overexpressed XIAP increases NF-κB activation. Interestingly, increasing amounts of FAF1 or a deletion mutant that contains the DEDID domain attenuates this effect. A similar effect has been reported between FAF1 and its interactor CD40 receptor. FAF1 binds with the CD40 receptor via its FID domain and inhibits CD40-induced NF-κB activity [53] . Considering that FAF1-XIAP interaction occurs through the XIAP BIR domains, FAF1 may directly prevent XIAP activation of NF-κB signaling, as has previously been observed with the XIAP interactors Smac/Diablo and SIVA. The Smac/Diablo protein, an antagonist of caspase inhibition, binds to the BIR3 domain of XIAP and inhibits the XIAP-TAB1 interaction via steric exclusion [17] , whereas SIVA attenuates NF-κB activation by binding both TAK1 and XIAP simultaneously [26] . However, the attenuation of XIAP-mediated NF-κB activation by direct interaction between XIAP and FAF1 does not occur. Our co-immunoprecipitation assays using HEK293T cells co-transfected with XIAP and increasing amounts of FAF1 show that FAF1 does not interfere with XIAP-TAB1 binding, in contrast to that observed with Smac/Diablo or SIVA. Therefore, FAF1 may indirectly hinder XIAPmediated NF-κB activation by either disrupting IKK complex formation or sequestering RelA/p65 to the cytosol but not through direct interaction with XIAP.
We also observed that FAF1 overexpression inhibits the NF-κB signaling pathway, which agrees with previous studies [36, 37] . XIAP overexpression reverses this inhibition and induces strong NF-κB pathway activation. Interestingly, a XIAP deletion mutant lacking the RING domain, which does not stimulate NF-κB [13] , was still able to partially reduce the NF-κB inhibition induced by FAF1. These results confirm that XIAP activates the NF-κB signaling pathway but also indicate that XIAP acts as a direct inhibitor of the NF-κB suppressor FAF1. Because XIAP depends on its RING domain for ubiquitination but not for blocking FAF1 activity on the NF-κB pathway, XIAP may directly interfere with either FAF1 suppression of IKK activation or FAF1 cytoplasmic retention of RelA/p65. As we demonstrated, XIAP binds to the DEDID domain but not to the FID domain of FAF1; therefore, XIAP has the potential to block the interaction between FAF1 and RelA/ p65 but not the interaction between FAF1 and IKK. Our co-immunoprecipitation experiments indicated that XIAP inhibits FAF1-RelA/p65 interaction in a dose-dependent manner. Moreover, XIAP reduces the cytoplasmic sequestration of RelA/p65 by FAF1, thus allowing RelA/ p65 to accumulate in the nucleus. FAF1 ubiquitination by XIAP may also modulate FAF1 inhibition of NF-κB signaling, as shown for NF-κB inhibition by COMMD1 [54, 55] . Taken together, our results establish that XIAP regulates FAF1-mediated NF-κB inhibition through direct interaction with FAF1and modulating FAF1 degradation, resulting in the release of RelA/p65 from FAF1 inhibition. Thus, XIAP is the first protein identified that interacts with FAF1 and is able to regulate FAF1 activity in the NF-κB pathway through direct interaction and ubiquitination. However, FAF1 is still able to inhibit NF-κB by suppressing IKK activation. FAF1 may have a regulatory effect on cell protection against oxidative damage because NF-κB activation by XIAP increases the levels of mitochondrial antioxidants (SOD2 and TRX2) and decreases the production of intracellular reactive oxygen species (ROS) [56] .
We have described a novel interaction between FAF1 and XIAP that regulates their opposing functional roles on the apoptotic and NF-κB pathways. FAF1 promotes cell death by facilitating caspase activity and blocking the NF-κB pathway. This activity is counterbalanced by XIAP, which promotes survival through inhibiting caspases and modulating the NF-κB response. The interaction between XIAP and FAF1 and balancing their opposing effects may be critical in the development of diseases such as cancer. Genomic loss or downregulation of FAF1 expression has been observed in human uterine and gastric carcinomas [57, 58] , malignant mesothelioma [59] and ovarian cancer [60] , which also exhibit aberrant or higher NF-κB signaling activity [61] [62] [63] [64] .
XIAP is differentially overexpressed in many human cancers [4] and has been proposed as a chemoresistance factor in different tumors [5] . This role remains controversial and appears to depend on both the XIAP expression levels and the cellular regulatory pathways controlling its function [65] [66] [67] [68] [69] . XIAP only acts as a potent chemoresistance factor in cells lacking functional XIAP regulatory circuits [62] . Thus, the finely tuned balance between XIAP and its modulators is critical in determining the clinical outcome in cancer patients [67] . It is interesting to note that there are several cancers, such as ovarian, mesothelioma or gastric and cervical carcinomas, in which FAF1 is downregulated and XIAP appears to be overexpressed [66] [67] [68] [69] [70] . It is tempting to speculate that XIAP activity promoting the survival of the tumor cells, as well as resistance to anti-cancer therapy, is unopposed because the FAF1 regulatory mechanisms are inactivated. However, further investigation is required to explore the correlation between FAF1 and XIAP expression levels and the potential clinical consequences.
Conclusions
Here, we characterized the novel interaction between XIAP and FAF1. We observed that XIAP blocks FAF1-induced cell death by downregulating FAF1 through an ubiquitination-mediated mechanism. Conversely, pro-apoptotic FAF1 is not able to interfere in the prosurvival activity of XIAP. Because both proteins inversely regulate the NF-κB pathway, we studied their influence on this signaling pathway when co-expressed. XIAP is able to interfere with the ability of FAF1 to sequester cytoplasmic p65 but does not hinder attenuation of the NF-κB response by FAF1. Taken together, our data establish a new interaction between XIAP and FAF1 and show the existence of new cellular mechanisms through which these two proteins regulate apoptotic and non-apoptotic processes. 
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